Match tier Institution-verified
Presence Current · Arkansas
Last published 2025
Sources Institutional record
Refreshed 2026-08-06

Sri J Obulareddy

Sourced from institutional research profiles (UAMS TRI or ARA).

Associate Professor

Faculty Researcher

COM | Internal Med Hem-Onc

2 h-index 6 pubs 21 cited

  • Humans
  • Immune Checkpoint Inhibitors
  • Carcinoma, Hepatocellular
  • Liver Neoplasms
  • Tumor Microenvironment
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols
  • Fatigue
  • Female
  • Indazoles
  • Male
  • Middle Aged
  • Neoplasms
  • Neutropenia

Edit your profile

Biography and Research Information

OverviewAI-generated summary

Sri J Obulareddy's research focuses on the burden and trends of various cancers across different global regions, with a particular emphasis on projections of future deaths. Recent publications investigate the burden and trends of colorectal cancer in high-income Asia Pacific countries, tracheal, bronchus, and lung cancer in Southeast Asia, East Asia, and Oceania, and stomach cancer attributable to smoking in South Asia. These studies utilize comparative and benchmarking analyses to assess cancer mortality from 1990 to 2019 and project outcomes to 2040. Obulareddy also contributes to medical case studies, including a case of herpes simplex virus meningitis in an immunocompromised individual and an instance of aplastic anemia mimicking myelofibrosis. Obulareddy collaborates with researchers such as Sara Suleman, Eric O. Gomez Urena, Faraaz A Yousuf, and Hamza Mirza at the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 2
  • Publications: 6
  • Citations: 21

Selected Publications

  • Multimodal reprogramming of the tumor microenvironment by MMR and dual checkpoint blockade in hepatocellular carcinoma models (2025)
    Frontiers in Immunology 1 citation DOI OpenAlex
  • Disparities in Leukemia Incidence and Mortality By Sex and Race in the United States from 1999 to 2020: A Retrospective Longitudinal Cross-Sectional Study Using Joinpoint Regression and Negative Binomial Analysis (2024)
    Blood DOI OpenAlex
  • The role of gut microbiota augmentation in managing non-alcoholic fatty liver disease: an in-depth umbrella review of meta-analyses with grade assessment (2024)
    Annals of Medicine and Surgery 3 citations DOI OpenAlex
  • Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024)
    Cancers 2 citations DOI OpenAlex
  • 526P Burden and trends of tracheal, bronchus, and lung (TBL) cancer in Southeast Asia, East Asia, and Oceania from 1990-2019, and its projection of deaths to 2040: A benchmarking analysis (2023)
    Annals of Oncology DOI OpenAlex
  • 177P Burden of stomach cancer attributable to smoking in South Asia from 1990-2019, its projection of deaths to 2040: A benchmarking and comparative analysis (2023)
    Annals of Oncology DOI OpenAlex
  • 116P Burden and trends of colorectal cancer in high income Asia Pacific countries from 1990-2019 and its projections of deaths to 2040: A comparative analysis (2023)
    Annals of Oncology 1 citation DOI OpenAlex
  • Aplastic Anemia Mimicking Myelofibrosis: A Diagnostic Dilemma (2023)
    Cureus DOI OpenAlex
  • A Case of Herpes Simplex Virus Meningitis in an Immunocompromised Individual: Avoiding Common Diagnostic Pitfalls (2023)
    Cureus 3 citations DOI OpenAlex

Grants & Funding

As listed on this researcher's institutional profile.

  • 276883 S2212, Shorter Anthracycline-Free Chemo Immunotherapy Adapted Topathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study SouthWest Oncology Group Principal Investigator
  • 276250 Alliance A011801,COMPASSHER2 Trials:COMPASSHER2 Residual Disease, A Double-Blinded, Phase III Randomized Trial of T-DM1&Placebo Compared with T-DM1 and Tucatinib Alliance for Clinical Trials in Oncology Principal Investigator
  • 276249 Alliance A012103, OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy Alliance for Clinical Trials in Oncology Principal Investigator

Collaboration Network

58 Collaborators 37 Institutions 4 Countries

Top Collaborators

View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics